论文部分内容阅读
目的观察吡格列酮对新发高血压伴单纯性肥胖患者的血压、血脂及胰岛素水平的影响。方法将60例新发高血压伴单纯性肥胖的患者分为吡格列酮加生活方式干预治疗组和氨氯地平加生活方式干预治疗组,治疗12周,观察治疗前后两组患者血压、血脂、体质量指数及空腹胰岛素水平的变化。结果吡格列酮加生活方式干预具有明显的降压、降脂作用,患者的体质量指数,空腹胰岛素水平明显下降;氨氯地平加生活方式干预也具有明显的降压、降低空腹胰岛素水平作用,体质量指数虽有下降,但差异无统计学意义。结论吡格列酮可改善伴胰岛素抵抗的高血压患者的胰岛素敏感性,具有降压、降脂作用。
Objective To observe the effects of pioglitazone on blood pressure, blood lipid and insulin levels in patients with newly diagnosed hypertension complicated with simple obesity. Methods Sixty patients with newly diagnosed hypertension complicated with simple obesity were divided into two groups: pioglitazone plus lifestyle intervention group and amlodipine plus lifestyle intervention group. After 12 weeks of treatment, blood pressure, blood lipid, body weight Index and fasting insulin levels. Results Pioglitazone combined with lifestyle intervention had obvious antihypertensive and lipid-lowering effect, and the body mass index and fasting insulin level decreased significantly. Amlodipine plus lifestyle intervention also had obvious antihypertensive effect, reduced fasting insulin level and body weight Although the index decreased, the difference was not statistically significant. Conclusion Pioglitazone can improve the insulin sensitivity of hypertensive patients with insulin resistance, with antihypertensive and lipid-lowering effects.